A Phase I, Multi-center, Open-label Study of LEE011 in Patients With Malignant Rhabdoid Tumors and Neuroblastoma
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2019
At a glance
- Drugs Ribociclib (Primary)
- Indications Neuroblastoma; Rhabdoid tumour
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 25 Oct 2018 Status changed to discontinued.
- 09 Aug 2017 Status changed from active, no longer recruiting to completed.
- 15 May 2017 Planned End Date changed from 1 May 2017 to 19 Jun 2017.